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Abstract
Background Patients with chronic hepatitis C genotype 1
(HCV-1) and difﬁcult-to-treat characteristics respond
poorly to pegylated interferon alfa and ribavirin (RBV),
and could beneﬁt from an interferon with increased activity
(consensus interferon or CIFN), favorable viral kinetics
from daily dosing, and a longer duration of therapy. The
purpose of this pilot study was to determine the efﬁcacy
and safety of daily CIFN ? RBV for initial treatment of
patients with HCV-1 infection.
Methods Patients with difﬁcult-to-treat characteristics
(92% male, 33% African American, 78% Veterans Affairs
[VA]; 67% high viral load, 59% stage 3–4 ﬁbrosis, and
mean weight of 204 lbs) were enrolled at seven VA and
two community medical centers. They were randomized to
daily CIFN (15 mcg/day SQ) and RBV (1–1.2 g/d PO)
given for either 52 weeks (group A, n = 33) or
52–72 weeks (from time of viral response ?48 weeks)
(group B, n = 31).
Results Intention to treat analysis for treatment groups
A and B demonstrated 33% (11/33) and 32% (10/31)
sustained virologic response (SVR), respectively. Only
2/31 patients in group B received more than 52 weeks
of treatment. The overall group demonstrated a 31%
(20/64) rapid virologic response rate (RVR), 54% (34/64)
end of treatment virologic response and a 33% (21/64)
SVR. Patients with RVR at 4 weeks, early virologic
response from 8–12 weeks, and late virologic response
from 16–24 weeks demonstrated SVR of 75% (15/20),
31% (4/13), and 22% (2/9), respectively. Overall early
non-protocol discontinuation occurred in 26/64 (40%)
patients.
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DOI 10.1007/s10620-010-1504-yConclusion Daily CIFN and ribavirin for initial treatment
of HCV-1 patients has potential for achieving a relatively
high RVR rate, but discontinuations are frequent and suc-
cessful use of this regimen is highly dependent on adequate
patient support to maintain adherence.
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Introduction
Hepatitis C virus (HCV) is a leading cause of chronic liver
disease in the United States, often resulting in cirrhosis,
liver failure, or hepatocellular carcinoma in infected indi-
viduals [1]. The projected mortality due to HCV-related
liver disease and hepatocellular carcinoma is expected to
total over 200,000 individuals between 2010 and 2019 in
the United States [2]. Current treatment for hepatitis C
largely consists of pegylated interferon alfa 2a plus riba-
virin or pegylated interferon alfa 2b plus ribavirin [3]. This
treatment is inadequate for many patients with HCV
genotype 1, since the majority of these patients studied in
registration trials do not respond (termed non-responders)
or respond but relapse (termed relapsers) following termi-
nation of treatment [4–7]. Characteristics that are associ-
ated with a worse response to treatment include genotype 1
infection and high viral blood levels, increased body mass
index, African American ethnicity, male gender, and the
presence of advanced liver ﬁbrosis. Data from a multi-
center Veterans Affairs (VA) study indicate that a higher
percentage of patients in the VA system have these char-
acteristics, which may be responsible for poor treatment
response rates [8]. A large retrospective review of SVR
rates in veterans with chronic hepatitis C indicated that
SVR was attained in only 20% of patients with treatment
naı ¨ve genotype 1 patients treated with pegylated interfer-
ons and ribavirin [9].
Consensus interferon (CIFN), also known as interferon
alfacon-1 or Infergen, is a non-naturally occurring type-1
interferon that was derived by scanning the sequences of
several nonallelic natural interferon alpha subtypes and
assigning the most frequently observed amino acid in each
corresponding position, producing a consensus sequence.
CIFN differs from interferon alfa-2a and interferon alfa-2b
by 19 and 18 amino acids, respectively. CIFN has been
shown to have greater biologic activity relative to other
interferons, which may be explained by the fact that CIFN
binds with higher afﬁnity to the interferon receptor com-
plex, producing greater signaling output and increased
production of interferon stimulated genes [10–13].
Several clinical studies have suggested that CIFN may
have greater antiviral activity in both treatment naı ¨ve and
prior treatment nonresponder patients with genotype 1
hepatitis C infection, particularly if given as a daily
injection [14–18]. These data suggested that a strategy
using daily CIFN may be more effective for genotype 1
HCV patients than currently available treatments with
pegylated interferons and ribavirin. Emerging data also
suggest that patients who have a ‘‘late’’ early virologic
response, meaning that they have a virologic response
(deﬁned as a negative HCV PCR test) on pegylated inter-
feron and ribavirin therapy between 12 and 24 weeks, will
have an improved sustained response rate if they are treated
for up to 72 weeks compared with 48 weeks [19, 20].
These data suggest the hypothesis that patients who have a
‘‘late’’ early virologic response with CIFN and ribavirin
between 12 and 24 weeks may also beneﬁt from a course
of therapy that is extended to up to 72 weeks in duration.
Therefore, the goals of this pilot study are to determine
the tolerability and efﬁcacy of daily CIFN plus ribavirin
when given for 52 weeks or an extended duration of
therapy. The target population was recruited from centers
with higher percentage of patients with difﬁcult-to-treat
characteristics, which include the following characteristics:
genotype 1, a North American patient population, pre-
dominantly male gender, and VA location.
Methods
Study protocol
This is an investigator-initiated randomized, open label,
multicenter, U.S.-based trial. The primary objective of the
study was to provide pilot data on the efﬁcacy and toler-
ability of daily CIFN and ribavirin given for 52 weeks in
patients with chronic hepatitis C genotype 1. The trial was
designed to study genotype 1 patients with difﬁcult-to-treat
characteristics, and included primarily male patients at
VA medical centers. The secondary objective was to obtain
pilot data to determine the feasibility of treating patients
for longer than 52 weeks based on the time of initial viral
response during the ﬁrst 24 weeks. All patients gave
informed consent and the study was approved by the
institutional review boards of all study sites. The study was
registered with ClinicalTrials.gov identiﬁer NCT00211692.
Allpatientsthatenrolledwererandomizedata1:1ratioto
daily CIFN (15 mcg day
-1 SQ) and ribavirin (1–1.2 g
day
-1 PO)givenforupto52 weeks(groupA)ordailyCIFN
(15 mcg d
-1 SQ) and ribavirin (1–1.2 g day
-1 PO) given
from 52 to 72 weeks (group B) depending on the time to
achieving viral negativity (Fig. 1).
The presence of HCV in serum was determined by
several HCV quantitative tests from week 4 through week
20. The type of assay varied between sites and changed
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123over the course of the study from 2005 to 2008. Assays
used included the AMPLICOR HCV MONITOR Test v2.0,
Roche Diagnostics, Pleasanton, CA (lower limit of detec-
tion 600 IU ml
-1); COBAS
 TaqMan
 HCV Test, lower
limit of detection 25–50 IU ml
-1, Roche Diagnostics,
Pleasanton, CA; and Abbott Celera HCV Quantiﬁcation
ASR Assay, Abbott Park, IL (lower limit of 25 IU ml
-1).
We deﬁned a negative quantitative test as \600 IU ml
-1
for the purposes of this study. Subsequent HCV levels at
week 24, end of treatment, and at 24 weeks after the end of
treatment were determined using a qualitative HCV poly-
merase chain reaction (PCR) test (COBAS
 AMPLICOR
HCV Test, v2.0, and AMPLICOR
 HCV Test, v2.0, Roche
Diagnostics, Pleasanton, CA), with at least a lower limit of
detection of 50–100 IU ml
-1. Viral negativity through
week 20 was deﬁned as below the lower limit of detection
with a quantitative test of at least\600 IU ml
-1; and viral
negativity at week 24, end of treatment, and end of follow-
up was deﬁned as below the lower detection limit of the
qualitative assay of at least \100 IU ml
-1. A rapid viro-
logic response (RVR) is deﬁned as viral negativity at week
4; an early virologic response is deﬁned as C2-log decrease
in viremia or viral negativity at week 12; and an end of
treatment response (ETR) is deﬁned as viral negativity at
the end of the treatment. A late virologic response (LVR) is
deﬁned as viral negativity occurring between week 12 and
week 24. A sustained virologic response (SVR) is deﬁned
as a negative qualitative HCV PCR test taken 24 weeks
after the end of CIFN/ribavirin therapy.
For patients in group A, if there was a C2-log drop in
viremia at week 12 the therapy was continued. If the
patient had a negative qualitative PCR test for HCV RNA
at week 24 they continued to be treated for a total of
52 weeks. The treatment was discontinued if they did not
have a C2-log drop at week 12 or if they did not become
negative for HCV RNA by qualitative PCR by 24 weeks on
therapy.
For patients in group B, early virologic response was
determined every 4 weeks to week 20 and 24, until a
virologic response was demonstrated (deﬁned as a C2-log
drop in viral levels from baseline or undetectable viral
load) by quantitative PCR. Once patients attained a viro-
logic response by quantitative PCR their treatment was
continued for an additional 48 weeks. (For example, for
patients who had less than a two log drop at week 4, but
attained a C2-log drop in viral levels by quantitative PCR
at week 8, the recommended duration of treatment was
8 weeks ? 48 weeks = 56 weeks. Similarly, if a patient
attained a virologic response only by week 20, then the
recommended duration of treatment was 20 weeks ?
48 weeks = 68 weeks. Also, if patients did not attain a
2-log drop by week 20 but had a negative qualitative PCR
at 24 weeks, then total recommended treatment duration
was 24 ? 48 weeks = 72 weeks). The minimal duration
of 52 weeks was chosen because this provided 48 weeks of
treatment beyond the ﬁrst viral negative point at 4 weeks.
Again as in group A, treatment was discontinued if patients
did not become negative for HCV RNA by qualitative PCR
by 24 weeks on therapy.
Patients were required to have active HCV genotype 1
infection and have no obvious contraindications for anti-
viral treatment, documentation of the presence of circu-
lating hepatitis C virus by a positive hepatitis C PCR test, a
positive HCV genotype test for genotype 1, and a liver
biopsy (within the previous 5 years) that is compatible with
chronic hepatitis. Patients were between the ages of 18 and
65 years. Patients were enrolled according to current
community standards of care and individual physician
judgment and there were no speciﬁc exclusions for pre-
existing psychiatric or substance abuse co-morbidities.
Female patients of childbearing age were required to have a
negative pregnancy test at entry within 48 h of starting
treatment and practice contraception. Patients were
required to have compensated liver disease with the
Fig. 1 Study design and patient
outcome
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123following laboratory results at entry: hemoglobin C12 g
dl
-1 for females and C13 g dl
-1 for males, white blood
count C2,000 mm
-3, neutrophil count C1,500 mm
-3,
platelets C75,000 mm
-3, albumin C3.0 g dl
-1, total bili-
rubin\2.0, serum creatinine B1.4 mg dl
-1,I N RB1.8, and
TSH within normal limits.
Growth factors were allowed in this study as per current
standard practice, but only after and in the context of the
dose reduction schedule for CIFN and ribavirin. Step-wise
dose reductions for changes in hemoglobin, platelets, and
white blood count was performed as appropriate and as
indicated by the protocol. Patients who developed anemia
deﬁned as Hg\10 g dl
-1 were managed by reducing the
dose of ribavirin in 200 mg increments. Patients that
developed neutropenia deﬁned as absolute neutrophil count
\0.75 9 109 l
-1 or thrombocytopenia deﬁned as platelet
count \50 k l
-1 were managed by stepwise dose reduc-
tions of CIFN to 12, 9, or 6 lg day
-1.
Statistical Analysis
Chi-squared test was used to compare signiﬁcant differ-
ences between study arms. Logistic regression analysis was
used to determine predictors of SVR. Statistical analyses
were performed using Microsoft Excel version 2007 and
SPSS software version 16.0 (SPSS, Chicago, IL).
Results
Patients
A total of 64 patients were recruited for this study at nine
sites in the United States. All patients received daily CIFN
(15 mcg day
-1 SQ) and RBV (1–1.2 g day
-1 PO) given
for at least 52 weeks. In addition, at enrollment 33 patients
were randomized into group A, receiving 52 weeks of
treatment, and 31 patients were randomized into group B,
receiving 52–72 weeks of treatment depending on time to
viral undetectability within the ﬁrst 24 weeks.
Baseline demographic and clinical characteristics of all
treatment naı ¨ve, HCV genotype 1 patients who received
CIFN and RBV are presented in Table 1. Overall, the
patients were 94% male, 33% African American, 69% had
high viral load (HCV RNA levels [800,000 IU ml
-1),
55% stage 3–4 ﬁbrosis, and mean weight was 204 lb.
The large majority of patients (80%) were from VA
medical centers. Comparison of the characteristics of the
randomized groups indicated that both study groups were
well matched with no signiﬁcant differences between
groups.
Antiviral Efﬁcacy
In order to evaluate the antiviral efﬁcacy of CIFN on the
entire patient cohort a pooled analysis of patients in both
groups A and B was conducted. Note that deﬁnitions of
PCR negative were based on the use of a HCV quantitative
test from weeks 4 to 20 and a HCV qualitative test from
week 24 and after (see ‘‘Methods’’). Intention to treat
analysis showed that 31% (20/64) of patients demonstrated
a rapid virologic response (RVR) at 4 weeks (Fig. 2a). In
addition, 20% (13/64) were complete early virologic
responders (EVR) between 8 and 12 weeks and 14% (9/64)
were late virologic responders (LVR) between 12 and
24 weeks. As depicted in Fig. 2a, 52% of patients overall
were viral negative by week 12, 52% were viral negative
by week 24, and 42% were viral negative by week 52.
Overall, 66% (42/64) achieved undetectable viral levels at
some point by week 24, but this includes nine patients that
dropped out early and were later categorized as treatment
failures. Overall, in intention to treat analysis the ﬁnal SVR
rate was 33% (21/64) (Fig. 2a). Separately, there were no
signiﬁcant differences in viral negativity rates between
treatment groups A (36%; 12/33) and B (48%, 15/31)
through 52 weeks (Fig. 2a). Similar ﬁnal SVR rates were
noted in treatment arm A (33%; 11/33) and treatment arm
B (32%; 10/31) (Fig. 2a, b). Of note, only two patients of
the eight eligible patients in treatment arm B received more
than 52 weeks of treatment. Six of eight patients eligible
for extended duration of therapy beyond 52 weeks stopped
therapy due to noncompliance, intolerance of side effects
and breakthrough viremia.
Table 1 Baseline patient characteristics
Characteristic Treatment
group A
Treatment
group B
Total
Caucasian 22/33 (67%) 19/31 (61%) 41/64 (64%)
African American 11/33 (33%) 10/31 (32%) 21/64 (33%)
Other 0/33 (0%) 2/31 (7%) 2/64 (3%)
VA patients 26/33 (79%) 25/31 (81%) 51/64 (80%)
Non-VA patients 7/33 (21%) 6/31 (19%) 13/64 (20%)
Severe ﬁbrosis
(stage III–IV)
17/33 (52%) 18/31 (58%) 35/64 (55%)
Mild ﬁbrosis (stage I–II) 16/33 (48%) 13/31 (42%) 28/64 (45%)
High viral load
([800,000 IU/ml)
24/33 (73%) 20/31 (65%) 44/64 (69%)
Low viral load
(\800,000 IU/ml)
9/33 (27%) 11/31 (35%) 20/64 (31%)
Male 32/33 (97%) 28/31 (90%) 60/64 (94%)
Female 1/33 (3%) 3/31 (10%) 4/64 (6%)
Average weight 207 ± 35 lb 202 ± 38 lb 204 ± 36 lb
VA Veterans Affairs
No signiﬁcant (P\0.05) differences between treatment arms
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and ﬁnal SVR results are summarized in Table 2. Patients
with RVR demonstrated a 75% (15/20) SVR. Patients with
complete EVR and LVR demonstrated 29% (6/21) and 0%
(0/1) SVR, respectively. Per-protocol analysis including
patients who received 80% of the planned CIFN and
ribavirin dose through at least week 52 and who took the
medication 80% of the time (80/80/80 compliance),
revealed an overall SVR rate of 85% (11/13) (Table 2;
Fig. 2b). Univariate analysis of possible predictors of SVR
(viral load, ﬁbrosis stage, race, RVR, and 80/80/80 com-
pliance) indicated that patients with 80/80/80 compliance
had signiﬁcantly higher SVR rates compared to those who
did not (P\0.05).
We noted a high degree of variance in terms of SVR
rates and early discontinuation of patients from treatment
within the ﬁrst 24 weeks at different study sites. Figure 3
illustrates four centers with the greatest numbers of
patients, and compares the percent of patients with early
virologic response, SVR, and early discontinuation within
the ﬁrst 24 weeks. These data indicate a trend toward an
inverse correlation between SVR rate and early discontin-
uation rates. Although this analysis is limited by low
numbers of patients and variable numbers of African
American patients at each site, these data suggest the
importance of each site in maintaining patient adherence to
therapy and ﬁnal SVR rate.
Safety and Tolerability
There was an increased rate of dose reduction and dis-
continuation before the recommended duration of treat-
ment (Table 3). Overall, during treatment 61% (39/64) of
patients required CIFN dose reduction and 41% (26/64)
required RBV dose reduction. The timing and reasons for
CIFN and RBV dose reduction are indicated in Fig. 4a
and b. Dose reductions tended to occur early during the
Fig. 2 Patient outcomes. a Percentage of patients with negative
hepatitis C virus polymerase chain reaction (HCV PCR) results over
time for total cohort and patients in groups A and B. Results include
HCV quantitative PCR negative (week 4–20) and HCV qualitative
PCR negative (week 24, end of treatment [week 52?]) and end of
follow up (week 72?) data. Note: patients who were HCV PCR
negative but subsequently dropped out were considered as treatment
failures from the time of drop out. b Sustained virologic response
(SVR) analysis by study arm and overall SVR result for total cohort.
Intention to treat (ITT) and overall per protocol SVR rates
Table 2 Sustained virologic response (SVR) based on patient
characteristics
Group Number
of patients
SVR (%)
RVR (week 4) 20 15/20 (75%)
Total EVR (C2-log drop week 12) 29 8/29 (28%)
Partial EVR (C2-log drop but
detectable week 12)
8 2/8 (25%)
Complete EVR (PCR negative
at week 12)
21 6/21 (29%)
LVR (week 24) 1 0/1 (0%)
Caucasian 41 18/41 (44%)
African American 21 3/21 (14%)
Stage 4 ﬁbrosis 22 7/22 (32%)
Stage 0–3 ﬁbrosis 42 14/42 (33%)
High VL ([800 k IU/ml) 43 14/43 (32%)
Low VL (\800 k IU/ml) 21 7/21 (33%)
80% Compliant (80/80/80) 13 11/13 (85%)
RVR rapid virologic response, EVR early virologic responders,
PCR polymerase chain reaction, LVR late virologic response
Fig. 3 Patient outcomes by study site. Sites with greater than eight
patients enrolled were compared (sites A–D), and other study sites
with lower enrollment were grouped together (other low enrollment
sites). AA African American
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123course of treatment. Early discontinuation of treatment
before 24 weeks occurred in 40% (26/64) of patients (12
due to intolerance, 11 due to noncompliance, 1 due to chest
pain, and 2 due to cellulitis), as indicated in Fig. 5.
Treatment discontinuations due to serious adverse events
occurred in two patients, which were hospitalizations due
to chest pain and encephalopathy, respectively. Overall,
discontinuations due to adverse events or noncompliance
occurred in 50% of patients, with the greatest number of
discontinuation occurring in the ﬁrst 12 weeks. Discon-
tinuation due to virologic non-efﬁcacy occurred in 15.6%.
As indicated in Table 3, signiﬁcant differences were
observed between groups A and B in numbers of patients
with discontinuations for ‘‘Discontinuations due to adverse
events or noncompliance’’ and ‘‘Discontinuations due to
virologic non-efﬁcacy’’, but overall there was no differ-
ence in overall discontinuations between the two groups
(P = 0.29). The reason for the differences between groups
in these two types of discontinuations is unknown, as they
occurred in both groups before the 52-week point when
there was no difference in treatment and can only be attrib-
uted to the small sample size. In addition there was a sig-
niﬁcant difference in ‘‘Patients requiring G-CSF’’, but again
this is unexplained and likely due to the small sample size.
Discussion
The purpose of this study was to determine the efﬁcacy and
safety of a regimen of daily CIFN and ribavirin in HCV
genotype 1 patients with ‘‘difﬁcult to treat’’ characteristics.
This multicenter study enrolled patients that were 94%
male and 33% African American, with 80% of patients at
VA medical centers. In addition, the majority of these
patients had advanced ﬁbrosis and a high viral load. On an
Table 3 Safety analysis
Treatment discontinuations Group A
(N = 33)
Group B
(N = 31)
Total
(N = 64)
Serious adverse events
a 1 (3.2%) 1 (3.2%) 2 (3.1%)
Discontinuations due to
adverse events or
noncompliance
22 (66.7%) 10 (32.2%)
b 32 (50.0%)
Discontinuations due to
virologic non-efﬁcacy
2 (6.1%) 8 (25.8%)
c 10 (15.6%)
Patients requiring
erythropoetin
4 (12.1%) 3 (9.7%) 7 (10.9%)
Patients requiring G-CSF 0 5 (16.1%)
d 5 (7.8%)
a SAEs that resulted in hospitalization included chest pain and
encephalopathy
b P = 0.01
c P = 0.04 (total discontinuations for any reason P = 0.29)
d P = 0.02
Fig. 4 Dose reductions. a Number and reasons for incidences of
consensus interferon (CIFN) dose reduction. b Number and reasons
for incidences of ribavirin (RBV) dose reduction
Fig. 5 Number and reasons for incidences of treatment discon-
tinuation
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virologic response and an overall 33% SVR rate. This trial
failed to test the difference between 52 weeks of treatment
vs. variable treatment duration of 52–72 weeks, due to the
fact that so few patients required or were able to comply
with therapy beyond 52 weeks of treatment. Overall, we
observed frequent early discontinuation of therapy due to
noncompliance or side effects; however, there was a wide
variation in patient compliance between sites. Patients that
adhered with at least 80% of the prescribed dose of CIFN
and ribavirin for 80% of the prescribed duration to
52 weeks achieved an 85% SVR rate.
Prior clinical studies of CIFN and ribavirin have indi-
cated mixed results. Pockros et al. reported 40 treatment
naı ¨ve patients in community/academic practices, 50–55%
genotype 1, who received either CIFN 9 lg/day with
ribavirin 1,000–1,200 mg/d or CIFN 9 lg/d alone [21].
They found that 65% of patients who received CIFN and
ribavirin required dose reductions, with an overall 35%
discontinuation rate. The overall SVR rate in patients
receiving CIFN and ribavirin was 40%. On the other hand,
several clinical studies reported greater antiviral responses
with CIFN in patients with genotype 1 hepatitis C infec-
tion, particularly if given as a daily injection. Recent
data indicate that 15 lg CIFN given three times a week
with ribavirin has an equivalent SVR rate to pegylated
interferon alfa-2a and ribavirin in patients with HCV
genotype 1 [16].
Preliminary data have also indicated that up to 39–47%
HCV genotype 1 patients who do not respond to interferon
alfa-2b ? ribavirin may respond to daily induction dosing
of CIFN (18 or 27 lg/d for 4 weeks followed by 9 or
18 lg/d for 8 weeks, then 9 lg/d for 36 weeks) with the
addition of ribavirin and have a sustained virologic
response [14]. Furthermore, Kaiser et al. [15] have shown
that daily high dose induction dosing of CIFN with riba-
virin therapy results in sustained response rates in about
one quarter of previous pegylated interferon and ribavirin
non-responders. Kaiser et al. have also published pre-
liminary data treating treatment-naive genotype 1 patients
in Germany with daily high doses CIFN and ribavirin for
48 weeks. They found that 59–67% of genotype 1 patients
experienced a sustained virologic response [14]. Leevy
et al. [17] recently reported that U.S. patient nonresponders
to pegylated interferon and ribavirin who receive daily
CIFN (15 lg) and ribavirin can achieve a 37% sustained
virologic response rate. Bacon et al. [18] in the multicenter
DIRECT trial treated patients who were prior pegylated
interferon and ribavirin nonresponders with CIFN (9 or
15 lg/d) and ribavirin and found an overall 6.9–10.7%
SVR rate. In two relapse studies, CIFN was compared to
pegylated interferon showing greater efﬁcacy at either 15
or 9 lg/d (69% vs. 42% and 47% vs. 29%, respectively)
[22, 23]. However, to date there have been no published
direct comparisons of daily CIFN and ribavirin with
pegylated interferon and ribavirin for HCV treatment naı ¨ve
or nonresponder patients. Given the mixed results, our data
emphasizes the difﬁculties in tolerance of this regimen, and
adequate patient support is essential and may explain the
differences reported between centers.
The overall 33% SVR rate obtained in the genotype 1
patients in this study compares favorably with the few prior
reports of the efﬁcacy of pegylated interferon and ribavirin
for male predominant VA patients with HCV genotype 1.
Backus et al. [9] reported an overall 20% SVR rate for
HCV genotype 1 patients who received pegylated inter-
feron and ribavirin in the national VA HCV registry
database. Single VA centers have reported SVR rates of
15–33% in smaller numbers of patients [24–26].
Patients treated with daily CIFN and ribavirin demon-
strated a 31% rapid virologic response rate, deﬁned as a
HCV PCR test below the limit of detection on a quantita-
tive PCR assay at 4 weeks. One limitation of this study was
the use of a quantitative PCR test during weeks 4–20, with
lower limits of detection from 100 to 600 IU ml
-1.I n
addition, the methods used for HCV PCR tests varied from
site to site. Therefore the data presented may overestimate
the true viral negative rate because of the sites using an
assay with a lower limit of detection of 600 IU ml
-1.I fw e
limited the analysis to sites that used a quantitative assay
with a lower limit of detection of 50 IU ml
-1 we observe
that 12/51 (23.5%) patients were HCV PCR negative at
week 4 and therefore have a rapid virologic response. This
can be compared with another U.S. trial of genotype 1
treatment naı ¨ve patients treated with either pegylated
interferon alfa-2a or alfa-2b and ribavirin, which demon-
strated a 11.4–11.9% rapid virologic response rate [7]. In
contrast, recent European trials examining the relevance of
extended therapy based on virologic response in patients
with HCV genotype 1 treated with pegylated interferon alfa
and ribavirin used HCV PCR assays with a lower limit of
detection of 50 IU ml
-1 to determine virologic response at
4 weeks [19, 20]. These studies found that 19–22% of these
patients had a rapid virologic response. In addition, it
remains unknown how CIFN will be used in the upcoming
era of targeted therapy, but treatment strategies associated
with a high initial RVR may be important when consid-
ering the addition of more speciﬁc antivirals in order to
reduce the chance of viral mutations and for determination
of duration of therapy [27].
Patients in this trial were observed to have a relative
high early discontinuation rate of 40% within the ﬁrst
24 weeks and a 50% overall discontinuation rate due to
adverse events and noncompliance. This is only some-
what higher than previous early discontinuation rates pub-
lished for comparable male predominant VA type patient
886 Dig Dis Sci (2011) 56:880–888
123populations. For example, Brau et al. [28] reported a 30.5%
discontinuation rate for adverse events during treatment in
a 785 patient VA cohort treated with standard interferon
alfa and ribavirin. Backus et al. [9] reported that 62% of
patients received less than the targeted full treatment
duration in a retrospective analysis of 5,944 patients in the
VA Clinical Case Registry for hepatitis C treated with
pegylated interferon and ribavirin. Note that this includes
patients that were discontinued for any reason, including
lack of efﬁcacy in addition to presumed adverse events,
and the number of patients that discontinued within the ﬁrst
24 weeks of treatment was not reported. In contrast, studies
from registration trials of pegylated interferon and ribavirin
reported discontinuation rates for adverse events of
14.0–22% [4, 5, 29]. In addition, Bacon et al. [18] reported
a 21% discontinuation rate due to adverse events in the
DIRECT registration trial patients treated with daily CIFN
and ribavirin using dosing similar to the present study.
Note that this trial included only patients with previous
treatment experience, who were nonresponders to prior
treatment with pegylated interferon and ribavirin and
motivated to receive repeat treatment. These data indicate
that treatment discontinuation reﬂects the patient popula-
tion in addition to the type of regimen used. Furthermore,
we observed that compliance with treatment and discon-
tinuation rates correlated with study site, which may be
another explanation for the relatively overall high discon-
tinuation rate observed in this study. These data emphasize
the importance of supportive care for continuing patients
on daily CIFN and ribavirin treatment. Overall we found
that daily CIFN and ribavirin was safe in these patients,
with only 2 (3.1%) serious adverse events reported, which
is comparable with the rate of serious adverse events in a
recent U.S. trial of pegylated interferon alfa-2a and alfa-2b
with ribavirin [7].
In conclusion, daily CIFN and ribavirin for initial
treatment of HCV-1 patients with a high incidence of
difﬁcult-to-treat characteristics results has potential for
achieving a relatively high rapid virologic response rate,
but discontinuations are frequent and successful use of this
regimen is highly dependent on adequate patient support to
maintain adherence.
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